Martin David Harp, Associate Editor, Ophthalmology Times

Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.

Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.

Sherrol Reynolds, OD, FAAO, said that multimodel imaging has been a game changer in assessing the choroidal function and structural changes in various disease conditions.

Roya Attar gives an overview of her presentation, "Decoding the Retina: The Value of Genetic Testing In Inherited Disorders," presented with Mohammad Rafieetary, OD, FAAO, FORS, ABO, ABCMO.

Ian Ben Gaddie, OD, FAAO, outlines key findings from a recent study evaluating lotilaner in patients with Demodex blepharitis and meibomian gland dysfunction.

Clark Chang, OD, MSA, MSc, FAAO, discussed the complexities of diagnosing keratoconus in his Rapid Fire presentation given at the American Academy of Optometry 2024 meeting.

The weekly drug-eluting contact lens was created by the company’s proprietary 3D printing technology and met all primary end points with no serious adverse events reported in either cohort.

The TECNIS Odyssey IOL is a new full vision range IOL built on the TECNIS platform.

The study looked at bevemipretide, which targets the inner mitochondrial membrane where it reversibly binds to cardiolipin.

Veligrotug is an intravenously delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody.

Top-line data from the trial evaluating phentolamine ophthalmic solution 0.75% for the treatment of presbyopia are expected in 2025.

Results suggest higher exposures to lower temperatures and certain air pollutants could result in worsened ocular symptoms and increased tear osmolarity.

The trial will evaluate repeat dosing of axitinib intravitreal implant, (AXPAXLI) for the treatment of patients with wet AMD.

The primary endpoint will be pain improvement as measured by visual analogue scale (VAS) compared to placebo.

The company also submitted a marketing authorization application with the European Medicines Agency.

Apellis will seek re-examination from the CHMP following the opinion, according to a news release.

The company expects enrollment of the GAZE phase 1, open-label clinical trial, to begin in the second half of 2024.

The new policy will work to encourage grant-making entities to fund post-market research investigating pharmacodynamics and pharmacokinetics for generic drugs that did not adequately enroll women, and sexual and gender minority populations in their clinical trials.

The launch of the nutritional supplement follows a clinical trial that demonstrated healthy tear production and provided noticeable relief of dry eye symptoms in as little as 2 to 4 weeks.

InflammaDry is a diagnostic test that detects elevated levels of MMP-9, an inflammatory marker consistently found in the tears of patients with DED.

Michael Belin, MD, weighs the ABCD and Amsler-Krumeich classifications and proposes ABCD progression displays as an effective modern alternative.

Phase 3 trials continue to investigate the efficacy of EpiSmart, a new method of cross-linking that could be utilized in the treatment of keratoconus.

Kourtney Houser, MD, and Kendall Donaldson, MD, MS, give an overview of the important role topography and tomography play in catching keratoconus early in their patients.

Annual follow-ups for patients with keratoconus can help them become better candidates for cross-linking procedures, according to William Trattler, MD.

The trial evaluates OCU410ST, a modifier gene therapy candidate utilizing an AAV delivery platform for the retinal delivery of the RORA gene. The gene therapy is being designed as a one-time treatment for life.

Early diagnosis of keratoconus is vital given the disease's prevalence in pediatric patient, according to Jennifer Harthan, OD, FAAO, FSLS.

Shelley Cutler, OD, FAAO, comments on technological advancements leading to the progression of keratoconus diagnosis and treatment options during this year's IKA symposium.

Melissa Barnett, OD, Director of Optometry at the University of California, Davis, talked about her session at IKA that focused on keratoconus from the patient perspective.

Elizabeth Yeu, MD, Executive Board Member of IKA, and a cataract and refractive surgeon at Virginia Eye Consultants, talked about cataract surgery in keratoconus, and the diagnostic considerations clinicians can take before and in the operating room.

Justin Schweitzer, OD, FAAO, from Vance Thompson Vision, talked about his session at the IKA Symposium that discussed cross-linking in keratoconus treatment both now and looking toward the future.